Banco Santander (SAN) 4.56 $SAN
Santander Holdings USA, Inc. Provides Update on Form 10-Q Filing
PR Newswire - Tue Aug 30, 12:00PM CDT
Santander Holdings USA, Inc. (the "Company"
, will be delayed in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (the "Form 10-Q" beyond its August 22, 2016 extended filing date.
SC: 12.45 (+0.07), SAN: 4.56 (+0.04)
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
The Zacks Analyst Blog Highlights: UBS Group AG, Deutsche Bank, Bank of New York Mellon and Banco Santander
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: UBS Group AG, Deutsche Bank, Bank of New York Mellon and Banco Santander
SAN: 4.56 (+0.04), DB: 14.90 (+0.21), UBS: 14.71 (+0.25), BK: 41.65 (+0.18)
Big Banks Team Up to Develop Blockchain Settlement System
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:25PM CDT
Wall Street's increasing focus on digital currency technology has been affirmed yet again with the recent teaming up of a group of financial giants for the development of Utility Settlement Coin (USC).
SAN: 4.56 (+0.04), GS: 169.18 (+0.67), JPM: 67.49 (+0.28), C: 47.51 (+0.15), DB: 14.90 (+0.21), UBS: 14.71 (+0.25), BK: 41.65 (+0.18)
VIDEO: Sanofi - Q2 2016 Results Interview with CEO Olivier Brandicourt
PR Newswire - Fri Jul 29, 12:46AM CDT
Sanofi, a global and diversified healthcare leader, reports results for the second quarter of 2016. CEO Olivier Brandicourt comments on the results.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
PR Newswire - Wed Jul 27, 7:12PM CDT
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
New Four-Strain Influenza Vaccine, VaxigripTetra(TM), Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
PR Newswire - Thu Jun 23, 6:56AM CDT
New VaxigripTetra(TM) vaccine:
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Watch List for Foreign Money Center Banks Equities -- Banco Santander, Barclays, Lloyds Banking Group, and Credit Suisse Group
PR Newswire - Wed Jun 15, 7:00AM CDT
On Tuesday, June 14, 2016, the NASDAQ Composite ended the trading session at 4,843.55, down 0.10%; the Dow Jones Industrial Average edged 0.33% lower to finish at 17,674.82; and the S&P 500 closed at 2,075.32, down 0.18%. Stock-Callers.com has initiated coverage on the following equities: Banco Santander S.A. (NYSE: SAN), Barclays PLC (NYSE: BCS), Lloyds Banking Group PLC (NYSE: LYG), and Credit Suisse Group A.G. (NYSE: CS). Learn more about these stocks by accessing their free trade alerts at:
BCS: 9.31 (+0.18), SAN: 4.56 (+0.04), CS: 13.27 (+0.13), LYG: 3.31 (+0.01)
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 80.85 (-0.08), SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 80.85 (-0.08), SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes
PR Newswire - Wed May 25, 5:50PM CDT
Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. The 15-member panel voted 12 to 2 (1 panelist did not vote due to travel) to approve the fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Santander Celebrates Branch Relocation To Union Square Area With Non-Profit Donation And Ribbon Cutting
PR Newswire - Wed May 25, 10:53AM CDT
Santander Bank celebrated the relocation of one of its Manhattan branches today from the Flatiron District to a more visible and highly trafficked location just outside Union Square. The Bank marked the occasion with a $5,000 donation to the pioneering non-profit organization, Third Street Music School Settlement, the nation's longest-running community music school located just a few short blocks away from the branch in its new East Village neighborhood.
SAN: 4.56 (+0.04)
Why is Barclays (BCS) a Must Buy Foreign Bank Stock Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:18AM CDT
At a time when most foreign banks are struggling to regain foothold amid a challenging operating backdrop, Barclays is portraying a different picture. Let's check its strengths and the reasons to add this stock to your portfolio now.
BCS: 9.31 (+0.18), SAN: 4.56 (+0.04), BBVA: 6.36 (+0.07), ITUB: 11.31 (+0.17)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Santander Opens New Branch At Boston Medical Center
PR Newswire - Thu May 19, 10:53AM CDT
Santander Bank celebrated the opening of its newest Massachusetts branch at Boston Medical Center (BMC) today, furthering its commitment to the first-class healthcare facility. Executives and team members from Santander and BMC attended the grand opening and ribbon cutting to officially open the branch at 850 Harrison Avenue in Boston.
SAN: 4.56 (+0.04)
Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine
BusinessWire - Mon May 16, 8:00AM CDT
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Sanofi Sends Letter to Medivation's Board of Directors
Globe Newswire - Thu May 05, 7:24AM CDT
Sanofi Sends Letter to Medivation's Board of Directors
MDVN: 80.85 (-0.08), SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Santander Holdings USA, Inc. Provides Update on Form 10-Q Filing
PR Newswire - Tue Aug 30, 12:00PM CDT
Santander Holdings USA, Inc. (the "Company"
, will be delayed in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (the "Form 10-Q" beyond its August 22, 2016 extended filing date. SC: 12.45 (+0.07), SAN: 4.56 (+0.04)
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
The Zacks Analyst Blog Highlights: UBS Group AG, Deutsche Bank, Bank of New York Mellon and Banco Santander
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: UBS Group AG, Deutsche Bank, Bank of New York Mellon and Banco Santander
SAN: 4.56 (+0.04), DB: 14.90 (+0.21), UBS: 14.71 (+0.25), BK: 41.65 (+0.18)
Big Banks Team Up to Develop Blockchain Settlement System
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:25PM CDT
Wall Street's increasing focus on digital currency technology has been affirmed yet again with the recent teaming up of a group of financial giants for the development of Utility Settlement Coin (USC).
SAN: 4.56 (+0.04), GS: 169.18 (+0.67), JPM: 67.49 (+0.28), C: 47.51 (+0.15), DB: 14.90 (+0.21), UBS: 14.71 (+0.25), BK: 41.65 (+0.18)
VIDEO: Sanofi - Q2 2016 Results Interview with CEO Olivier Brandicourt
PR Newswire - Fri Jul 29, 12:46AM CDT
Sanofi, a global and diversified healthcare leader, reports results for the second quarter of 2016. CEO Olivier Brandicourt comments on the results.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
PR Newswire - Wed Jul 27, 7:12PM CDT
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
New Four-Strain Influenza Vaccine, VaxigripTetra(TM), Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
PR Newswire - Thu Jun 23, 6:56AM CDT
New VaxigripTetra(TM) vaccine:
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Watch List for Foreign Money Center Banks Equities -- Banco Santander, Barclays, Lloyds Banking Group, and Credit Suisse Group
PR Newswire - Wed Jun 15, 7:00AM CDT
On Tuesday, June 14, 2016, the NASDAQ Composite ended the trading session at 4,843.55, down 0.10%; the Dow Jones Industrial Average edged 0.33% lower to finish at 17,674.82; and the S&P 500 closed at 2,075.32, down 0.18%. Stock-Callers.com has initiated coverage on the following equities: Banco Santander S.A. (NYSE: SAN), Barclays PLC (NYSE: BCS), Lloyds Banking Group PLC (NYSE: LYG), and Credit Suisse Group A.G. (NYSE: CS). Learn more about these stocks by accessing their free trade alerts at:
BCS: 9.31 (+0.18), SAN: 4.56 (+0.04), CS: 13.27 (+0.13), LYG: 3.31 (+0.01)
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 80.85 (-0.08), SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 80.85 (-0.08), SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes
PR Newswire - Wed May 25, 5:50PM CDT
Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. The 15-member panel voted 12 to 2 (1 panelist did not vote due to travel) to approve the fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Santander Celebrates Branch Relocation To Union Square Area With Non-Profit Donation And Ribbon Cutting
PR Newswire - Wed May 25, 10:53AM CDT
Santander Bank celebrated the relocation of one of its Manhattan branches today from the Flatiron District to a more visible and highly trafficked location just outside Union Square. The Bank marked the occasion with a $5,000 donation to the pioneering non-profit organization, Third Street Music School Settlement, the nation's longest-running community music school located just a few short blocks away from the branch in its new East Village neighborhood.
SAN: 4.56 (+0.04)
Why is Barclays (BCS) a Must Buy Foreign Bank Stock Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:18AM CDT
At a time when most foreign banks are struggling to regain foothold amid a challenging operating backdrop, Barclays is portraying a different picture. Let's check its strengths and the reasons to add this stock to your portfolio now.
BCS: 9.31 (+0.18), SAN: 4.56 (+0.04), BBVA: 6.36 (+0.07), ITUB: 11.31 (+0.17)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Santander Opens New Branch At Boston Medical Center
PR Newswire - Thu May 19, 10:53AM CDT
Santander Bank celebrated the opening of its newest Massachusetts branch at Boston Medical Center (BMC) today, furthering its commitment to the first-class healthcare facility. Executives and team members from Santander and BMC attended the grand opening and ribbon cutting to officially open the branch at 850 Harrison Avenue in Boston.
SAN: 4.56 (+0.04)
Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine
BusinessWire - Mon May 16, 8:00AM CDT
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
Sanofi Sends Letter to Medivation's Board of Directors
Globe Newswire - Thu May 05, 7:24AM CDT
Sanofi Sends Letter to Medivation's Board of Directors
MDVN: 80.85 (-0.08), SAN: 4.56 (+0.04), SNY: 39.18 (+0.77)
